European doctors shared their views on a joint strategy of EMA and the Heads of Medicines Agencies for the next five years. We recognise the EMA’s role in increasing transparency and overview of the marketing status of centrally authorised medicines and underline the importance of gathering robust evidence before the approval of any new medicine not to put patient’s health at risk.
Read our response to public consultation here.